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The remarkable pro-apoptotic properties of tumour necrosis factor (TNF)-related 
apoptosis-inducing ligand (TRAIL) have raised considerable interest as an anticancer 
therapeutic. However, in several cancer cells TRAIL was found to be largely ineffective in 
inducing apoptosis. In colon adenocarcinomas, post-translational modifications including O- 
and N- glycosylation of death receptors were found to correlate with TRAIL-induced apoptosis. 
Additionally, mRNA levels of fucosylation enzymes FUT3 and FUT6 were found to be high in 
TRAIL-sensitive COLO 205. Now we have used agonistic receptor-specific TRAIL variants to 
dissect the contribution of FUT3 and FUT6-mediated fucosylation to the apoptosis induction 
of TRAIL via its two death receptors (DR4 and DR5). Triggering of apoptosis by TRAIL 
revealed that the low FUT3/6 expressing DLD-1 and HCT 116 are insensitive to DR5 but not 
to DR4-mediated apoptosis. In contrast, efficient apoptosis is mediated via both receptors in 
high FUT3/6 expressing COLO 205. Reconstitution of FUT3/6 expression in DR5-resistant 
cells completely restored TRAIL sensitivity via this receptor, while only marginally enhancing 
apoptosis via DR4 at lower TRAIL concentrations. Interestingly, we observed that induction of 
the salvage pathway by simple external administration of L-fucose restores DR5-mediated 
apoptosis in both DLD-1 and HCT 116. Finally, we show that the fucosylation influences the 
ligand-independent receptor association leading to increased DISC formation and caspase-8 
activation. Taken together, these results provide evidence for a differential impact of 
fucosylation on the signalling via DR4 or DR5. These findings provide novel opportunities to 
enhance TRAIL sensitivity in colon adenocarcinoma cells that are highly resistant to DR5-





Colorectal cancer is the third most commonly diagnosed cancer in males and the second 
in females as estimated by the International Agency for Research on Cancer in 201828. Although 
early detection methods, increased awareness and improved treatment modalities have led to a 
reduction of both incidence and cancer death rates in several western countries, colorectal 
neoplasias are still one of the most deadly cancers, causing around 880,000 deaths worldwide 
every year28. The 5-year survival rate of colorectal cancer patients for localized-stage is 90%, 
but decreases to 71% and 14% for regional and distant stage respectively29. Although some 
relatively new strategies are developed to predict surgical resection more accurately such as 
“watch and wait” strategy and Narrow-band Imaging International Colorectal Endoscopic 
Classification (NICE)30,31. Thus, novel therapies are required to improve the prognosis of 
colorectal cancer patients. 
The TNF superfamily member TRAIL has gathered considerable attention as a potential 
cancer therapeutic, as it is able to induce apoptosis selectively in tumour cells while leaving 
normal cells unharmed32–34. TRAIL is capable of signalling via two apoptosis-inducing 
transmembrane death receptors (DRs), named DR4 (TRAIL-R1) and DR5 (TRAIL-R2). 
TRAIL also binds to three decoy receptors: DcR1 (TRAIL-R3), DcR2 (TRAIL-R4) and the 
soluble decoy receptor osteoprotegerin (OPG)35,36. Decoy receptors are unable to transduce 
death-inducing signals as they lack a functional intracellular death domain (DD)36–39, and they 
can diminish apoptosis activation by competing with TRAIL-DR interactions37,40 or by forming 
non-signalling heterotrimeric complexes41.  
Binding of trimeric recombinant human TRAIL (rhTRAIL) to death receptors triggers the 
intracellular formation of the so-called death inducing signalling complex (DISC), consisting 
of Fas-associated death domain (FADD), which further recruits and activates pro-caspase-8 
and/or pro-caspase-1042–45. Activation of initiator caspases leads to direct cleavage and 
activation of executioner caspases-3 and -7 and subsequent apoptosis induction through the 
extrinsic apoptotic pathway46–49. Activated caspases also lead to the cleavage of Bid (tBid), 
resulting in the release of mitochondrial factors, cleavage of caspase-9 and activation of effector 
caspases leading to apoptosis via the intrinsic pathway50. Despite its reported tumour selective 
properties, several studies showed that approximately 50% of the colorectal cancer cell lines 
are resistant to rhTRAIL51,52. Untagged soluble human TRAIL Dulanermin developed for 
clinical use was shown to have a half-life of only 23 to 31 min in non-human primates in 
preclinical tests, which was attributed to its low mass53. In order to improve half-life some 
TRAIL-R1/R2 agonist antibodies have been developed, which have a higher mass and therefore 
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a prolonged half-life. However, Mapatumumab (HGS-ETR1), TRAIL-R1 agonistic antibody, 
in Phase II clinical trial did not show satisfactory activity with refractory colorectal cancer 
patients54. This was shown due to the resistance of colorectal cancer cell lines to TRAIL51,52,55. 
The current focus is to use combination strategies to overcome TRAIL resistance. One case 
presentation from a Phase Ib open-labeled clinical study (NCT00671372) reported that the 
combination of Dulanermin and FOLFIRI stabilized the disease progress 56. The TRAIL-R2 
agonistic antibody, Conatumumab (AMG655) has been shown to be well-tolerated 
(NCT00819169) in various cancers including advanced colorectal cancer57. This clinical study 
is now continued to Phase II in combination with chemotherapeutic agents (NCT01327612).  
Fucosylation is an important type of post-translational modification in colon cancer58, in 
which fucose residues are terminally attached to N- or O-linked glycans or glycolipids59,60. This 
modification on the cell-surface is essential in numerous biological processes, such as ontogeny, 
cellular differentiation and signalling events59,61. All fucosyltransferases  require the donor 
substrate GDP-fucose, which can be synthesized from GDP-mannose by the dominant de novo 
pathway or from free L-fucose by the salvage pathway58,60,61. In the past years, several reports 
have described the importance of fucosylation in TRAIL-induced apoptosis in colon cancer. 
Wagner et al. firstly described the positive correlation between TRAIL sensitivity and mRNA 
levels of fucosyltransferase enzymes FUT3 and FUT6 in a panel of colon adenocarcinoma 
cells51. Furthermore, mutation of the GDP-mannose-4,6-dehydratase (GMDS) gene leads to the 
inactivation of the de novo GDP-fucose pathway and decreased TRAIL sensitivity, resulting in 
accelerated tumour growth in vivo, due to a lack of NK cell-mediated tumour surveillance50. 
GMDS also plays an important role in the formation of the FADD-dependent complex II, which 
comprises FADD, caspase-8 and c-FLIP. GMDS deficiency inhibited both DR4- and DR5-
mediated apoptosis by inhibiting the formation of the complex II, while it did not affect 
formation of the DISC or recruitment to and activation of caspase-862. The same group showed 
that fucosylation could be regulated through DNA methylation. Treatment with the novel 
methyltransferase inhibitor Zebularine was found to increase fucosylation levels, leading to 
enhanced TRAIL-induced apoptosis without increasing TRAIL receptor and/or caspase-8 
levels63. However, it is still unclear whether the fucosylation of DR4 and DR5 equally 
contributes to TRAIL-mediated apoptosis. Recently receptor specific agonists developed by us 
in the past have been used to unravel the respective contribution of DR4 and DR5 N-
glycosylation on TRAIL signalling18,64. 
Here we investigated the more precise role of fucosylation on DR4- and DR5-mediated 
apoptosis in colon adenocarcinomas, using TRAIL receptor-specific apoptosis-inducing 
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variants that bind selectively and with high affinity to either DR4 or DR518,24,65–67. We show 
that fucosylation of DR4 and DR5, either via the salvage or via the de novo synthesis pathway, 
enhances TRAIL signalling in colon adenocarcinoma cells. We were able to increase DR5-
mediated apoptosis in DR5 resistant colon cancer cell lines by improving the fucosylation status 





Variation in sensitivity to DR4- and DR5-mediated apoptosis among different colon 
adenocarcinomas 
To identify the sensitivity of colon adenocarcinoma cells to TRAIL via either DR4 or DR5, 
we investigated three cell lines: COLO 205, DLD-1 and HCT 116. By detecting the Annexin V 
levels induced by WT TRAIL, the DR4-specific TRAIL variant 4C7 and the DR5-specific 
TRAIL variant DHER, we found that COLO 205 was highly sensitive to TRAIL-mediated cell 
death via both death receptors (Fig. 1A). Cell death induction in DLD-1 and HCT 116 cells is 
primarily mediated by DR4 and not by DR5 as evidenced by the high Annexin V levels seen 
upon incubation with 4C7 but not DHER (Fig. 1B, C). We next used flow cytometry to 
determine if differences in surface expression of death receptors can explain the differential 
TRAIL sensitivity observed. We found that all three cell lines express DR5 to a similar extend 
(Fig. 1D). These results reinforce the notion that death receptor expression alone is not 
predictive of TRAIL susceptibility.  
 
Inhibition of O-glycosylation leads to loss of fucosylation resulting in a decrease of TRAIL 
sensitivity 
A role for fucosylation in TRAIL-induced apoptosis of colon adenocarcinomas has been 
previously implicated51,62,63,68. Wagner et al. tested a panel of 36 colorectal adenocarcinoma 
cell lines and found that the sensitivity to TRAIL correlated with increased mRNA levels of the 
O-glycosylation initiating enzyme GALNT3, as well as the O-glycan processing 
fucosyltransferase enzymes FUT3 and FUT651. However, they did not report the effect of 
inhibiting of glycosylation on the different death receptors (DR4 or DR5). Here we show that 
cell death induction via both DR4 and DR5 is hampered in COLO 205 upon pre-treatment with 
the pan O-glycosylation enzyme inhibitor benzyl 2-acetamido-2-deoxy- α-D-galactopyranoside 
(bGalNAc) (Fig. 2A). In DR4-sensitive HCT 116 cells, cell death induced by 4C7 was also 
significantly decreased after bGalNAc treatment (Fig. 2B). We have not detected changes in 
the level of cell death in the DR4/5-resistant human fibroblasts or in HCT 116 cells induced 
with DR5-specific rhTRAIL DHER (Fig. 2C). These results substantiate for both death 
receptors the importance of O-glycosylation and successive fucosylation for becoming sensitive 
to TRAIL-induced cell death.  
 




In order to investigate further the effect of fucosylation on TRAIL-induced apoptosis, we 
chose a fucosylation inhibitor to probe this effect in a cellular setting. Although most inhibitors 
only work in vitro[69, Rillahan et al. showed that 2F-peracetyl-fucose (2FF) is cell permeable 
and can be used in vivo70. We firstly examined the fucosylated oligosaccharides from DLD-1 
cells by blotting with recombinant biotinylated Aleuria aurantia lectin (AAL) which 
specifically binds to fucose71,72. Fig. 3A shows that the fucosylation level in DLD-1 cells 
reduced only after treatment with the high concentration of 2FF, which is in line with the 
observations from Rillahan et al.70.  Subsequently, we performed viability assays to explore 
alterations in the sensitivity of DLD-1 cells to rhTRAIL WT and DHER after adding 2FF. DLD-
1 cells were firstly treated with 2FF for 3 or 5 days, followed by 24h incubation with rhTRAIL 
WT or DHER. It can be seen from Fig. 3B that cell survival increased after incubating with the 
fucosylation inhibitor indicating that downregulation of fucosylation renders the receptor less 
sensitive for rhTRAIL WT and DHER. This decreased cell death induced by rhTRAIL DHER 
was further confirmed by flow cytometric analysis detecting apoptosis. Fig. 3C shows that 
frequency of early apoptotic cells decreased after pre-treatment with 500μM of 2FF, which 
means that low fucosylation levels lead to a reduction of rhTRAIL DHER-induced apoptosis. 
 
Triggering the fucosylation salvage pathway by L-fucose improves TRAIL sensitivity 
Fucosylation is an important type of post-translational modification in colon cancer58 and 
fucosyltransferase enzyme levels are important determinants. However, the presence of the 
donor substrate GDP-fucose is equally important. Therefore, we reasoned that targeting the de 
novo pathway or inducing the salvage pathway by increasing the level of GDP-fucose donor 
might enhance fucosylation and subsequently trigger TRAIL-mediated apoptosis. Recently, 
Moriwaki et al. showed that HCT 116 cells are less able to synthesize GDP-fucose, due to 
mutations in the GMDS gene that plays a critical role in the de novo GDP-fucose pathway62. 
We therefore investigated whether the salvage pathway can be activated by the addition of L-
fucose, and thereby potentially sensitize these cells to TRAIL-induced cell death. To do this, 
COLO 205, DLD-1, HCT 116, SW948 and WiDr cells were pre-incubated with L-fucose and 
after 24h further treated with rhTRAIL WT, 4C7 or DHER for 16h (0.05-500 ng/mL). The 
results show that the induction of DR5-mediated cell death is clearly enhanced upon pre-
treatment with L-fucose in DR5 resistant cell lines DLD-1, HCT 116, SW948 and WiDr (Fig. 
4B-E), with rhTRAIL DHER activities going up between 5 and 10 times in the presence of L-
fucose. In contrast to DHER sensitive COLO 205 cells, we only detected a slight enhancement 
of TRAIL-induced cell death using rhTRAIL DHER at low concentration (0.05 ng/mL) after 
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L-fucose pre-treatment (Fig. 4A). Since COLO 205, DLD-1 and HCT 116 are already quite 
sensitivity to 4C7, it is conceivable that it is difficult to increase the cell death at relative high 
concentration (50 or 500ng/mL). However, enhanced cell death was observed in COLO 205 
cells after treatment with low concentration 4C7 (Fig. 4A). The response to rhTRAIL WT was 
increased to an intermediate level in the presence of L-fucose reflecting its signalling via both 
DR4 and DR5. Enhanced cell death was not due to changed expression levels of DR4 and/or 
DR5 receptors (Fig. 5A), neither due to treatment by L-fucose alone (Fig. 5B).  
Taken together, these results indicate that L-fucose sensitizes DLD-1, HCT 116, SW948 
and WiDr to cell death through the activation of mainly DR5. 
 
Stable and transient overexpression of FUT3 and FUT6 enhances TRAIL sensitivity via 
both death receptors 
Our previous data show that upregulation of fucosylation by the salvage pathway indeed 
improves the sensitivity to TRAIL. Next, we focused on the two specific fucosyltransferase 
enzymes FUT3 and FUT6, which associate to TRAIL-sensitivity in colon cancer cells as 
reported by Wagner et al.. Quantitative PCR analysis confirmed the low mRNA levels of FUT3 
and FUT6 in our DR5-insensitive DLD-1 and HCT 116 cells (Fig. 6A), which correlates with 
previous observations51. We generated stable cell lines expressing either FUT3 or FUT6 in both 
DLD-1 and HCT 116. Cells were transduced either with an empty lentiviral vector (CTRL) or 
a vector expressing FUT3 or FUT6 with a  GFP gene, allowing for the selection of transduced 
cells. Using qRT-PCR a clear increase in relative FUT3 or FUT6 mRNA levels was observed 
compared to control with DLD-1 cells expressing higher levels of FUT3 and FUT6 compared 
to HCT 116 (Fig. 6A). Additional Western blot analysis of FUT3 expression, showed a 
significant increase in FUT3 protein levels in both DLD-1:FUT3 and HCT 116:FUT3 cells, 
when compared to control and FUT6 overexpressing cells (Fig. 6B). FUT6 protein levels could 
not be analyse with Western blot due to the lack of suitable antibodies. Flow cytometry analysis 
of transduced DLD-1 and HCT 116 cells showed that overexpression of FUT3 and FUT6 did 
slightly change the expression of DR4 and DR5, but not to a level that explains the change in 
sensitivity (Fig. 6C). 
To evaluate the impact of FUT3 or FUT6 stable overexpression on TRAIL-mediated 
apoptosis via either DR4 or DR5, the transduced cells were treated with 50 ng/mL of the 4C7 
or DHER, respectively. Overexpression of either FUT3 or FUT6 dramatically enhanced 
TRAIL-induced cell death via DR5 in both DLD-1 and HCT 116 cells (Fig. 6D). The sensitivity 
to rhTRAIL 4C7 in FUT3 or FUT6 overexpressing DLD-1 cells only slightly improved, 
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whereas cell death remained largely unaltered in overexpressing HCT 116 cells (Fig. 6D). This 
is mainly due to the already high cell death in control cells using 50 ng/mL rhTRAIL 4C7. 
Interestingly at low concentrations (5 ng/mL), where control DLD-1 cells show ~10 % of killing 
with rhTRAIL 4C7, transduced cells show an increase in killing cells, indicating that only at 
lower concentrations DR4-mediated cell death is slightly improved by the overexpression of 
fucosyltransferases (Fig. 6E). Moreover, to rule out the possibility that random integration of 
the gene into the genome itself could cause the differential TRAIL sensitivity we repeated the 
sensitivities assays with transient FUT3 and FUT6 overexpressing DLD-1 cells.  
Overexpressing FUT3 show a similar increase of TRAIL-induced cell death, which indicates 
that the observations are robust (Fig. 7A). Transient overexpression of FUT6 in both DLD-1 
and HCT 116 cells also enhanced the DR5 mediated cell death as seen by Annexin V-APC 
staining (Fig. 7B). In conclusion, FUT3 and FUT6 have a role in the regulation of TRAIL 
sensitivity via both death receptors and are most important for DR5. 
 
FUT3 and FUT6 overexpression leads to pre-clustering of DR4 and DR5  
Caspase-8 is very important in apoptotic signal transduction via ligand-dependent receptor 
activation. For TRAIL-mediated apoptosis, the signal is transmitted into the pathway by the 
formation of the DISC, which further recruits and activates caspase-873. To investigate whether 
the observed higher levels of apoptosis in FUT3 overexpressing cells were mirrored in the DISC 
formation, we co-immunoprecipitated the DISC proteins using FLAG-rhTRAIL WT (FLAG-
WT) and FLAG-DHER respectively. Caspase-8 activation was shown to be more pronounced 
in the DISC in control and FUT3 overexpression cells when immunoprecipitated with FLAG-
WT and less by FLAG-DHER (Fig. 8A). This is in line with the binding properties of FLAG-
WT, which can trigger the DISC formation via both DR4 and DR5, while FLAG-DHER can 
do this only via DR5. Notably, more DISC-associated caspase-8 was found in the S and T clonal 
populations of the FUT3 overexpressing cells as compared to the control cells, indicating that 
the level of apoptotic signaling activation in the FUT3 overexpressing cells is higher. We also 
show that DR5 participating in the DISC formation is more noticeable in the 
immunoprecipitates of FUT3 overexpressing cells, reinforcing the crucial response of DR5 to 
fucosylation (Fig. 8A). In a screen across a panel of breast cancer cell lines, TRAIL-sensitive 
cells showed more caspase-8 activity than TRAIL resistant cells74. This has also been found in 
a subset of colorectal cancer cell lines51. In order to examine caspase-8 and the downstream 
signal in more detail, we analyzed the pro-caspase-8, cleaved caspase-8 and downstream PARP-
1 activation. Western blot analysis demonstrated that activation and cleavage of caspase-8 and 
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PARP-1 was more pronounced in FUT3 and FUT6 overexpressing cells compared to control, 
which confirms that the effect of fucosylation is transmitted downstream in the apoptosis 
pathway (Fig. 8B). Moreover, the amount of cleaved caspase-8 and PARP-1 increased after the 
treatment with 4C7 and DHER, which indicated that this upregulation of fucosylation improved 
the DISC formation via both death receptors. We therefore investigated whether fucosylation 
enhanced TRAIL sensitivity by pre-clustering of DR4 and DR5 on the cell surface using 
immunofluorescent staining. Indeed, FUT3 and/or FUT6 overexpressing cells showed more 
pre-clustering of DR4 and DR5 compared to control cells (Fig. 8C). These results confirm that 
fucosylation by FUT3 and FUT6 overexpression enhances TRAIL-induced apoptosis through 
DISC formation by triggering the pre-clustering of DR4 and DR5. 
 
Discussion 
Recent results have shown that glycosylation of death receptors plays an important role in 
TRAIL-mediated apoptosis. In particular, it was shown that O-glycosylation increased TRAIL 
sensitivity by inducing efficient DISC formation and caspase-8 activation through the clustering 
of death receptors51. Moreover, the N-glycosylation of  human DR4 and mouse death receptor 
also regulates TRAIL-induced cell death by the enhancing DISC formation64. The death 
receptors can undergo successive post-translational modifications, such as fucosylation and 
sialylation that can occur after glycosylation. This fact , implies that there might be a connection 
and an additive effect in relation to TRAIL sensitivity60,75. Specifically, FUT3 and FUT6 
expression was shown to correlate with TRAIL sensitivity in a large panel of colorectal 
adenocarcinoma cell lines51. Moreover, GMDS deficiency leading to a loss of de novo 
fucosylation was found to increase tumour growth and metastasis in vivo62, due to a reduced 
FADD-dependent complex II formation68. Here, we provide for the first time evidence that 
signalling via DR5 is for the major part responsible for this L-fucose dependent apoptosis 
induction.  
In this study, we observed that DLD-1 and HCT 116 cells are highly insensitive to DR5-
mediated apoptosis in contrast to the colon adenocarcinoma COLO 205 cell line that shows a 
high sensitivity to both DR4- and DR5-mediated apoptosis. Here we further show that this 
insensitivity is not related to a lack of surface expression levels of DR5, but to a specific lack 
of fucosylation. This finding is in line with earlier observations that TRAIL-sensitive colon 
adenocarcinoma cell lines show relatively high mRNA levels of FUT3 and FUT6, while the 
TRAIL-resistant cell lines, such as DLD-1 and HCT 116, show low expression of FUT3 and 
FUT651,64.  Reduction of the number of fucosyl attachment sites by pre-treatment with the O-
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glycosylation inhibitor bGalNAc led to decreased TRAIL sensitivity via DR5 in all three cell 
lines mentioned, as determined by us using TRAIL-death receptor specific variants. The 
bGalNAc treatment also had an effect on the DR4 sensitivity in HCT 116, although there is a 
considerable residual activity. This may be due to the fact that DR4, in contrast to DR5, has N-
glycosylation sites, which are not affected by bGalNAc ensuing outstanding attachment sites 
for fucose. This observed reduction in DR4 signalling is slightly different from the data reported 
by Dufour et al., in which they reported that DR4-induced apoptosis in another bone 
osteosarcoma cell line was not at all affected by the bGalNAc treatment. This may due to the 
usage of a different cell line  and/or the use of a different DR4-specific variant64. Direct 
inhibition of fucosylation turned out to be complicated as most reported inhibitors do not 
penetrate into the cell and can be used only in vitro. By exploiting promiscuous monosaccharide 
salvage pathways the inhibitor 2FF can be partly imported and metabolized in cells70 and we 
indeed could show inhibition of fucosylation in DLD-1 colon cancer cells using high 
concentrations. The observation that the sensitivity to rhTRAIL DHER in these cells is lowered, 
forms an additional indication for the important role of fucosylation in activating death receptor. 
Without doubt, the most spectacular finding of our study is the observation that the simple 
addition of L-fucose re-sensitizes DLD-1 and HCT 116 cells to DR5-mediated apoptosis and 
enhances the DHER sensitivity from 5 to 40%. Interestingly, oral administration of L-fucose 
was found to successfully increase fucosylation in patient with leukocyte adhesion deficiency 
type II (LAD II), a rare inherited disorder of fucose metabolism76–78. Moreover, tumor growth, 
mitotic activity and metastases were greatly suppressed by daily intraperitoneal injection of L-
fucose in the Ehrlich carcinoma mice78. Our results further suggest that the sensitivity to TRAIL 
can be simulated after elevated expression of FUT3 or FUT6 in tumor cells, which is mainly 
mediated via DR5 as evidenced by the enhanced sensitivity to DHER of these cells.  
Further studies show that in FUT3/6 overexpressing cells compared to control cells, the 
pre-clustering of DR4 and/or DR5 is enhanced without any increase in the level of receptor 
expression. Moreover this clustering directly stimulates more DISC formation and caspase-8 
activation. In agreement with the regulation by O- or N-glycosylated death receptors, the 
upregulation of fucosylation changes the distribution of death receptors and enhances their 
clustering leading to enhanced apoptotic signal transduction after the stimulation by TRAIL24,51. 
There is some evidence showing that a pre-ligand assembly domain association (PLAD) 
consisting of death receptors, especially DR5, and decoy receptors lacking a death domain 
attenuates TRAIL-induced apoptosis41,79. In concert with this PLAD model, it can be conceived 
that if most death receptors are involved in the pre-clustering activity due to the upregulation 
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of fucosylation, the possibility for them to bind to the decoy receptors greatly decreases. By 
this mechanism, TRAIL induced apoptosis might become significantly improved upon 
fucosylation.       
Many examples have already shown the diagnostic applications related to fucosylation. 
The most representative type of cancer biomarker is fucosylated alpha-fetoprotein (AFP) in 
hepatocellular carcinoma (HCC). AFP with core fucosylation is very specific in the early stage 
of HCC and widely used as diagnostic marker80,81. Kyselova et al. measured the glycan profile 
in serum and proposed 8 potential sialylated and fucosylated N-glycan structures to stage the 
progression of breast cancer82. Moreover, in the serum from patients with advanced pancreatic 
cancer, haptoglobin fucosylation patterns were found that  differ from those at early stage83. 
Our results suggest that the status of fucosylation indicates the sensitivity to DHER in colon 
carcinoma and provides a potential biomarker for TRAIL therapy. Taken together, our findings 
give a new insight into the effect of post-translational modification on TRAIL-sensitivity and 




Materials and methods 
Cell lines and reagents 
Human colorectal cancer cell lines COLO 205, DLD-1,  HCT 116, SW948 and WiDr were 
cultured in RPMI1640 medium supplemented with 10% foetal calf serum (FCS), 100 units/mL 
Penicillin and 100 µg/mL Streptomycin in a humidified incubator at 37 °C containing 5% CO2. 
Human foreskin fibroblasts (Cell Stock, University of Groningen) were cultured in Ham’s F-
10 medium supplemented with 10% foetal calf serum (FCS), 100 units/mL Penicillin and 100 
µg/mL Streptomycin. All materials mentioned above were obtained from Thermofisher 
Scientific (Landsmeer, the Netherlands). rhTRAIL wild type (WT), the DR4-specific TRAIL 
variant 4C7 and the DR5-specific TRAIL variant DHER (amino acids 114-281) were 
constructed and produced as previously described18,64. L-(-)-Fucose (L-fucose), benzyl 2-
acetamido-2-deoxy-α-D-galactopyranoside (bGalNAc) and 2F-peracetyl-fucose (2FF) were 
purchased from Merck (Darmstadt, Germany).  
 
MTS assay 
Cell viability and proliferation assays were conducted using MTS assays. Cells were 
seeded in triplicate in 96-well plates at a cell density of 10,000 cells/well in 0.1 mL medium. 
After 24h, cells were treated with concentrations ranging from 0 to 500 ng/mL of rhTRAIL WT, 
4C7 or DHER for 16h, to a final volume of 0.15 mL. In the case of only L-fucose treatment, 
cells were incubated with different concentrations of L-fucose (0-100 mM) for 48h to a final 
volume of 0.2 mL. For the combination of L-fucose and rhTRAIL, cells were pre-incubated 
with 0 or 50 mM of L-fucose in a final volume of 0.15 mL. After 24h, cells were treated with 
concentrations ranging from 0 to 500 ng/mL of rhTRAIL WT, 4C7 or DHER for 16h to a final 
volume of 0.2 mL. Stock solutions of L-fucose were serially diluted in serum-free RPMI 
medium and TRAIL ligands in complete medium. Cells were incubated with MTS reagent 
according to manufacturer’s instructions (Promega, Leiden, the Netherlands). Cell viability was 
determined by measuring the absorption at 492 nm using a microplate reader (Thermo 
Labsystems). For inhibition of O-glycosylation, cells were pre-treated with 2 mM bGalNAc in 
a final volume of 0.15 mL. After 24h, cells were treated with rhTRAIL concentrations, ranging 
from 0 to 1000 ng/mL of rhTRAIL 4C7 or DHER for 16h, to a final volume of 0.2 mL. For 
inhibition of fucosylation, cells were seeded at the density of 1000 cells/well or 100 cells/well 
in 0.1 mL medium and incubated with 2FF at indicated concentration for 3 days and 5 days 





Apoptosis induction was measured using Annexin V-APC (IQP Products, Groningen, the 
Netherlands) staining and quantified by flow cytometry. Cells were seeded in 6-well plates 24h 
prior to treatment. The next day, cells were incubated with 0-500 ng/mL rhTRAIL WT, 4C7 or 
DHER for 16h. After treatment, cells were harvested and washed with calcium buffer (10.9 µM 
HEPES, 140 µM NaCl, 2.5 µM CaCl2) (Merck, Darmstadt, Germany). Cell pellets were 
resuspended in 60 µL calcium buffer complemented with 5 µL Annexin V-APC and incubated 
for 20 min on ice. Cells were washed and analysed using a FACS Calibur flow cytometer (BD 
Biosciences). For cells treated by 2FF, 3E5 cells were firstly seeded in one well of 6-wells plate. 
50 µM or 500 µM 2FF was added at the following day and incubated for 3 days. Three days 
later, 100 ng/ml rhTRAIL WT or DHER was added for 24h. After treatment, cells were 
harvested in PBS and apoptotic cells were measured and analysed by LSR-II (BD Biosciences) 
using dead cell apoptotic kit (Thermofisher Scientific, Landsmeer, the Netherlands). 
 
TRAIL receptor membrane expression analysis 
Cells were harvested and washed with FACS buffer (PBS with 1% BSA). Cell surface 
expression of TRAIL receptors was determined using 10 μg/mL TRAIL-R1, TRAIL-R2, 
TRAIL-R3, TRAIL-R4 (Alexis Biochemicals, Enzo Life Sciences, Bruxelles, Belgium) or 
negative control mouse IgG1 (Agilent, Santa Clara, USA). Cells were incubated with primary 
antibodies for 1h on ice. Subsequently, the cells were washed and incubated for 1h with R-
phycoerythrin (PE) conjugated goat anti-mouse antibody (Southern Biotech, Birmingham, USA) 
or Alexa Fluor 488 conjugated goat anti-mouse antibody (Thermofisher Scientific, Landsmeer, 
the Netherlands). Receptor cell surface expression was analysed using a FACS Calibur flow 
cytometer (BD Biosciences). 
 
Transient overexpression of FUT6-GFP and lentiviral overexpression of FUT3 and FUT6 
For transient overexpression of FUT6-GFP, DLD-1 and HCT 116 cells were seeded in 6-
wells plates at a density of 150,000 cells/well. The next day, the subconfluent cultures were 
transfected with plasmid containing GFP-conjugated α-1,3-fucosyltransferase 6, fuc-T6-GFP 
(FUT6-GFP) (a kind gift from prof. Jack Rohrer) using the FuGENE HD Transfection Reagent 
(Promega, Leiden, the Netherlands) according to manufacturer’s instructions. Cells were 
seeded 48h after transfection and treated with 50 ng/mL rhTRAIL WT, 4C7 or DHER for 16h. 
Cell death induction was measured using Annexin V-APC staining. 
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For lentiviral overexpression of FUT3 and FUT6, pLenti-GIII-CMV-GFP-2A-Puro 
plasmids encoding FUT3 or FUT6 and the control plasmid were purchased from Applied 
Biological Materials Inc. (Heidelberg, Germany). For the packaging of the lentiviral particles, 
2*106 HEK293 cells were plated in 94 mm cell culture dishes. The following day, cells were 
transfected with either pLenti-CMV-GFP vector expressing FUT3, FUT6 or the control vector, 
using CaCl2. After 48h, the medium containing virus particles was harvested, filtered, mixed 
with Polybrene (Merck, Darmstadt, Germany) and added to DLD-1 and HCT 116 cells, which 
were plated the day before at a density of 0.25*106 cells in a 6-wells plate; the final 
concentration of Polybrene was 10 µg/mL. The following day, the previous steps were repeated, 
therefore cells were exposed to the viral particles for 48h in total. Mixed populations of control-, 
FUT3- or FUT6-overexpressing cells were cultured in RPMI 1640 medium supplemented with 
10% foetal calf serum, 100 units/mL Penicillin, 100 µg/mL Streptomycin and 2 µg/mL 
Puromycin (Merck, Darmstadt, Germany) in a humidified incubator at 37 °C containing 5% 
CO2. Single clones that expressed GFP were subcloned. 
 
qRT-PCR 
RNA was isolated from DLD-1 and HCT 116 cells transduced with control, FUT3 or 
FUT6 lentiviral plasmids using the RNeasy Mini Kit (QIAGEN, Venlo, the Netherlands) 
according to manufacturer’s instructions. cDNA was synthesized from 4 µg total RNA using 
oligo dT primers and M-MLV Reverse Transcriptase (Thermofisher Scientific, Landsmeer, the 
Netherlands ) in a total volume of 80 µL. Quantitative real-time (qRT)-PCR was performed to 
determine the mRNA expression levels of FUT3 (5’- GGACATGGCCTTTCCACATC-3’ and 
5’-TCCAGGTGCTGGCAGTTAGG-3’), FUT6 (5’-CGCTTCCCAGACAGCACAGG-3’ and 
5’-TCCGTCCATGGCTTTCAGCTGCCA-3’) and the housekeeping gene RPL27 (5’-
TCCGGACGCAAAGCTGTCATCG-3’ and 5’-TCTTGCCCATGGCAGCTGTCAC-3’) 
using SsoAdvanced Universal SYBR Green Supermix (BioRad, Veenendaal, the Netherlands) 
on the CFX Connect Real-Time PCR Detection System (Bio-Rad). The protocol was as follows: 
initial denaturation at 98 °C for 3 min, followed by 45 cycles of amplification (5 sec at 98 °C 
and 20 sec at 65 °C). Finally, a melting curve analysis was performed to ensure that only a 
single PCR amplicon was produced. 
 
Western blotting 
Cells were harvested and lysed by using the Mammalian Protein Extraction Reagent 
(Thermofisher Scientific, Landsmeer, the Netherlands) with additional Protease Inhibitor 
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Cocktail, EDTA-Free (Roche, Basel, Switzerland). Protein concentrations were determined 
using a Bradford assay (Bio-Rad, Veenendaal, the Netherlands). Equal amounts of protein (20 
µg) for each sample were loaded per lane on pre-cast 4-12% SDS-PAGE gels (Thermofisher 
Scientific, Landsmeer, the Netherlands) and transferred onto Immobilon-FL PVDF 0.45 µm 
membranes (Merck, Darmstadt, Germany). Subsequently, the membranes were blocked for 1h 
at room temperature in blocking buffer (Rockland, Limerick, USA). Western blot membranes 
were probed overnight at 4 °C. The following primary antibodies were used: Caspase-8 (Cell 
Signalling Technologies, Leiden, the Netherlands), FUT3 (Abcam, Cambridge, UK) and 
PARP-1 (Cell Signalling Technologies, Leiden, the Netherlands). Goat-α-mouse-IRDye 680 
(LI-COR Biosciences, Nebraska, USA) or goat-α-rabbit-IRDye 800CW (LI-COR Biosciences, 
Nebraska, USA) secondary antibodies were used for detection using a LI-COR Odyssey 
Infrared Imaging System (Westburg). Membranes were probed with anti-γ-tubulin (Merck, 
Darmstadt, Germany) to confirm equal loading. For AAL blot, after proteins were transferred 
onto nitrocellulose membrane (Merck, Darmstadt, Germany), this membrane was blocked 
overnight in 3% BSA at 4 °C. Afterwards, membrane was incubated with 0.5 µg/ml of 
recombinant biotinylated AAL (Vector lab, Peterborough, UK) for 30 min at room temperature. 
Streptavidin conjugated with HRP (Thermofisher Scientific, Landsmeer, the Netherlands) used 
as secondary antibody was added for 30 min at room temperature. At last, membrane was 
detected using Pierce ECL kit (Thermofisher Scientific, Landsmeer, the Netherlands). Anti-β-
actin (Cell signalling technology, Leiden, the Netherlands) was probed as relative loading 
control. 
 
Co-immunoprecipitation of TRAIL-DISC complex 
M-270 Epoxy beads (Thermofisher Scientific, Landsmeer, the Netherlands ) were 
covalently coupled with anti-FLAG antibody (Merck, Darmstadt, Germany) according to the 
manufacture’s instruction (5-7 µg per mg beads) at 37°C for 20h. The next day beads were 
washed and stored following the protocol from the company. 3-4x107cells were harvested and 
incubated with 1 µg/mL FLAG-rhTRAIL or FLAG-DHER in the complete medium at 4°C to 
prevent ligand receptor complex internalization. After washing with PBS the cell pellet was 
weighted and nine volumes of the extracting buffer A (Thermofisher Scientific, Landsmeer, the 
Netherlands) supplemented with 50mM NaCl and protease inhibitor cocktail, were added and 
incubated on ice for 15min. Cell lysate was cleared by centrifugation at 2600xg for 5min at 4°C, 
then the DISC was co-immunoprecipitated overnight with the prepared beads at 4°C. Beads 
were washed three times with the extraction buffer A and one time with 1xLWB supplied with 
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the kit; then the protein complex was eluted using SDS loading buffer (50mM Tris-HCl, pH 
6.8, 2% SDS, 6% glycerol). 
 
Immunostaining of surface DR4 and DR5 
DLD-1:CTRL, DLD-1:FUT3 and DLD-1:FUT6 cells were seeded at a density of 150,000 
cells on Poly-L-lysine (Merck, Darmstadt, Germany) coated coverslips. Cells were fixed using 
4% formaldehyde solution (Merck, Darmstadt, Germany) for 15 min at room temperature. The 
cells were then stained for 1h with 1:50 in PBS diluted TRAIL-R1 (Alexis Biochemicals, Enzo 
Life Sciences, Bruxelles, Belgium), DR5-01-1 (Exbio, Praha, Czech republic) or IgG1 negative 
control (Agilent, Santa Clara, USA). After washing with PBS three times, cells were incubated 
with secondary antibody donkey anti-mouse IgG (H+L) Alexa Fluor 647 (Jackson 
ImmunoResearch, Cambridge, UK) at a concentration of 1:100 for 1h. Nuclei were 
counterstained with 0.2 µg/mL DAPI (Thermofisher Scientific, Landsmeer, the Netherlands) 
for 10 min. The coverslips were mounted with CitiFluor (Agar Scientific, Stansted, UK). Slides 
were photographed using a Leica DMI 6000 inverted microscope. 
 
Statistical analysis 
Data were presented as mean ± standard deviation (SD) from three independent 
experiments. Comparisons between groups were analysed by one-way ANOVA with GraphPad 
Prism version 5.00 (GraphPad Software, San Diego California, USA). Results were considered 
statistically significant at 5% level. P value was analysed by one-way ANOVA in Turkey’s 
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Figure 1. Different colon adenocarcinoma cell lines exhibit differential sensitivities via 
DR4 and DR5. Apoptosis inducing potential of rhTRAIL WT, 4C7 and DHER (0.05-500 
ng/mL) in COLO 205 (A), DLD-1 (B) and HCT 116 (C) was determined after 16h treatment 
using Annexin V-APC by flow cytometry. (D) Cell surface expression of TRAIL receptors was 
determined in COLO 205, DLD-1 and HCT 116 cells using flow cytometry analysis and 
depicted as the Mean Fluorescence Intensity (MFI) ratio (left graph) and as FACS histograms 
(right graph) compared to the binding of isotype antibody. The values shown are mean ± SD of 













































































Figure 2. Inhibition of O-glycosylation decreases TRAIL sensitivity. COLO 205 (A), HCT 
116 (B) and fibroblasts (C) were pre-treated with 2 mM bGalNAc for 24h, after which cells 
were stimulated with 1-1000 ng/mL rhTRAIL 4C7 or DHER for 16h. Cell death levels were 







Figure 3. Inhibition of fucosylaiton by adding 2F-peracetyl-fucose decreases sensitivity to 
DR5 specific TRAIL. (A) Proteins were blotted by recombinant biotinylated AAL and probed 
again by β-actin as loading control. (B) Cell survival was measured and analysed by MTS assay. 
The values shown are means mean ± SD of 3 independent experiments. (C) Cells were 
incubated with 2FF for 3 days and followed by adding 100 ng/mL rhTRAIL DHER for 24h. 





















































































































































Figure 4. L-fucose treatment augments TRAIL-induced apoptosis predominantly via the 
activation of DR5. COLO 205 (A), DLD-1 (B), HCT 116 (C), SW948 (D) and WiDr (E)  cells 
were pre-treated with 0 or 50 mM L-fucose for 24h and subsequently incubated with 0.05-500 
ng/mL rhTRAIL WT, DHER or 4C7 for another 16h. Cell death was assessed using MTS assay. 
Blue columns represent cells without adding L-fucose and red columns represent cells pre-
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Figure 5. DR4 and DR5 receptor expression and L-fucose tolerance. (A) Cell surface 
expression of TRAIL receptors was determined in DLD-1 and HCT 116 cells treated with 0 or 
50 mM L-fucose using flow cytometry analysis and expressed as the Mean Fluorescence 
Intensity (MFI) ratio compared to the binding of isotype antibody. (B) HCT 116 cells were 
treated with 0, 50 or 100 mM L-fucose and cell death was measured by FACS using Annexin 















































































































































































































































































































































Figure 6. FUT3 and FUT6 overexpression enhances TRAIL sensitivity of DLD-1 and HCT 
116 cells via both death receptors. Overexpression of FUT3 and FUT6 was analysed by qRT-
PCR of DLD-1 and HCT 116 cells transduced with control, FUT3 or FUT6 overexpressing 
plasmid. (A) The amount of FUT3 or FUT6 amplicon was relative to the endogenous reference 
RPL27 and normalized to the control cells. (B) Western blot analysis of control or FUT3/6 
transduced DLD-1 and HCT 116 cells. Lysates were examined for FUT3/6 expression levels; 
γ-tubulin served as a loading control. (C) The expression of DR4, DR5, DcR1 and DcR2 in 
Control, FUT3 and FUT6 overexpressing DLD-1 and HCT 116 cells. Cell death of transduced 
DLD-1 and HCT 116 cells overexpressing FUT3/6 was assessed after treatment with 50 ng/ml 
rhTRAIL 4C7 (D) or DHER (E) for 16h as measured by MTS assay. The values shown are 



































































Figure 7. TRAIL sensitivity of transient FUT3 or FUT6 transfected DLD-1 and HCT 116 
cells.  Transient FUT3 overexpressing DLD-1 cells were treated with 5-500 ng/ml rhTRAIL 
WT, 4C7 or DHER and cell death was measured by MTS assay (A). (B) Transient FUT6 
overexpressing cells lines DLD-1 and HCT 116 cells were treated with 50 ng/ml rhTRAIL WT, 
4C7 and DHER. Apoptosis induction was assessed after 16 h using Annexin C-APC staining 
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Figure 8. FUT3 and FUT6 overexpression leads to pre-clustering of DR4 and DR5. (A) Co-
immunoprecipitation of the TRAIL DISC. Two population of FUT3 overexpression cells (S 
and T) and control cells were stimulated by 1µg/mL FLAG-TRAIL WT or FLAG-DHER 
respectively for 0 or 30min. Then the DISC was immunoprecipitated with FLAG antibody. 
DR5 or cleaved caspase-8 from the DISC were detected by immunoblot. (B) Western blot 
analysis of FUT3 or FUT6 transduced DLD-1 cells treated with 500 ng/ml rhTRAIL WT, 4C7 
or DHER for 1h. Caspase-8 and PARP-1 activation was examined and analysed using 
densitometry (values depicted as % of total protein); γ-tubulin served as a loading control. The 
data are presented as mean values of 3 independent experiments. (C) Immunostaining of DLD-
1 cells transduced with control, FUT3 or FUT6 plasmids, containing the GFP gene. Cells were 
seeded on poly-L-lysine coated coverslips and stained with primary antibodies against DR4 or 
DR5, and secondary antibody conjugated with Alexa Fluor 647. Nuclei were counterstained 
with DAPI. The right graphs depict the quantification of the mean fluorescence intensity of 20 
single confocal pictures of each cell lines. 
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